Morgan Stanley’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.8K | Buy |
3,493
+453
| +15% | +$3.39K | ﹤0.01% | 6660 |
|
|
2025
Q4 | $25.6K | Sell |
3,040
-1,565
| -34% | -$17.3K | ﹤0.01% | 6615 |
|
|
2025
Q3 | $59.7K | Buy |
4,605
+91
| +2% | +$1.07K | ﹤0.01% | 6336 |
|
|
2025
Q2 | $44.1K | Buy |
4,514
+4,409
| +4,199% | +$46.5K | ﹤0.01% | 6401 |
|
|
2025
Q1 | $1.27K | Sell |
105
-390
| -79% | -$5.58K | ﹤0.01% | 7251 |
|
|
2024
Q4 | $7.62K | Sell |
495
-16,312
| -97% | -$308K | ﹤0.01% | 6889 |
|
|
2024
Q3 | $387K | Sell |
16,807
-53,006
| -76% | -$1.19M | ﹤0.01% | 5520 |
|
|
2024
Q2 | $1.35M | Sell |
69,813
-184,394
| -73% | -$4.94M | ﹤0.01% | 4795 |
|
|
2024
Q1 | $9.56M | Sell |
254,207
-95,644
| -27% | -$3.96M | ﹤0.01% | 3384 |
|
|
2023
Q4 | $10.6M | Buy |
349,851
+110,077
| +46% | +$2.4M | ﹤0.01% | 3865 |
|
|
2023
Q3 | $5.26M | Buy |
239,774
+86,784
| +57% | +$3.07M | ﹤0.01% | 3701 |
|
|
2023
Q2 | $5.95M | Buy |
152,990
+50,498
| +49% | +$4.46M | ﹤0.01% | 3637 |
|
|
2023
Q1 | $9.45M | Buy |
102,492
+489
| +0.5% | +$61.4K | ﹤0.01% | 3201 |
|
|
2022
Q4 | $14.6M | Sell |
102,003
-1,789
| -2% | -$446K | ﹤0.01% | 2660 |
|
|
2022
Q3 | $23.6M | Buy |
103,792
+1,683
| +2% | +$427K | ﹤0.01% | 2020 |
|
|
2022
Q2 | $23.9M | Buy |
102,109
+101,174
| +10,821% | +$22.2M | ﹤0.01% | 2088 |
|
|
2022
Q1 | $299K | Buy |
935
+39
| +4% | +$8.97K | ﹤0.01% | 5698 |
|
|
2021
Q4 | $250K | Sell |
896
-78
| -8% | -$13.4K | ﹤0.01% | 5949 |
|
|
2021
Q3 | $123K | Buy |
974
+41
| +4% | +$5.08K | ﹤0.01% | 6251 |
|
|
2021
Q2 | $154K | Buy |
933
+903
| +3,010% | +$184K | ﹤0.01% | 6142 |
|
|
2021
Q1 | $6K | Sell |
30
-957
| -97% | -$220K | ﹤0.01% | 7052 |
|
|
2020
Q4 | $222K | Buy |
987
+383
| +63% | +$78.4K | ﹤0.01% | 5538 |
|
|
2020
Q3 | $115K | Buy |
604
+454
| +303% | +$115K | ﹤0.01% | 5358 |
|
|
2020
Q2 | $36K | Sell |
150
-7,366
| -98% | -$1.45M | ﹤0.01% | 5792 |
|
|
2020
Q1 | $867K | Sell |
7,516
-5,811
| -44% | -$862K | ﹤0.01% | 4054 |
|
|
2019
Q4 | $2.22M | Buy |
13,327
+12,845
| +2,665% | +$6.5M | ﹤0.01% | 3953 |
|
|
2019
Q3 | $477K | Buy |
482
+384
| +392% | +$429K | ﹤0.01% | 4702 |
|
|
2019
Q2 | $113K | Sell |
98
-155
| -61% | -$141K | ﹤0.01% | 5266 |
|
|
2019
Q1 | $193K | Sell |
253
-178
| -41% | -$162K | ﹤0.01% | 5082 |
|
|
2018
Q4 | $415K | Sell |
431
-128
| -23% | -$169K | ﹤0.01% | 4898 |
|
|
2018
Q3 | $948K | Sell |
559
-226
| -29% | -$295K | ﹤0.01% | 4577 |
|
|
2018
Q2 | $804K | Buy |
785
+654
| +499% | +$704K | ﹤0.01% | 4766 |
|
|
2018
Q1 | $141K | Buy |
+131
| New | +$240K | ﹤0.01% | 5606 |
|
Other funds holding ACET
RCM
O
VCM
WP
PM
SCM
Morgan Stanley's ACET Position: Q1 2026 in Review
Morgan Stanley increased its Adicet Bio (ACET) stake by 15% in Q1 2026, buying an estimated $3.39K and bringing the position to 3,493 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6660.
Morgan Stanley first reported a position in ACET in Q1 2018 and has held it in 33 quarters since. The position peaked at $23.9M in Q2 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.
- Morgan Stanley held 3,493 shares of Adicet Bio worth $23.8K as of Q1 2026.
- Morgan Stanley bought 453 Adicet Bio shares in Q1 2026, an estimated $3.39K.
- Adicet Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6660 holding.
- Morgan Stanley first reported a position in Adicet Bio in Q1 2018 and has held it in 33 quarters since.
- Morgan Stanley's Adicet Bio position peaked at $23.9M in Q2 2022.
- 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.